報價延遲最少15分鐘:2025/05/13 18:51 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.251 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.30/-0.71
|
|
企業價值
11.46M
|
| 資產負債 |
|
每股賬面淨值
0.62
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
451.00K
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/13 18:51 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. |